Prenetics Global (NASDAQ:PRE) Stock Rating Lowered by Wall Street Zen

Prenetics Global (NASDAQ:PRE) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Monday.

A number of other equities research analysts have also recently issued reports on the company. Cantor Fitzgerald upped their target price on Prenetics Global from $26.00 to $32.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a report on Thursday, January 22nd. Finally, Roth Mkm assumed coverage on shares of Prenetics Global in a research report on Wednesday, February 11th. They set a “buy” rating and a $36.00 target price for the company. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Prenetics Global presently has a consensus rating of “Hold” and a consensus target price of $34.00.

Prenetics Global Stock Performance

PRE opened at $21.97 on Monday. The company has a market cap of $369.76 million, a PE ratio of -10.82 and a beta of 0.35. The stock has a 50-day moving average of $17.26 and a 200-day moving average of $13.64. Prenetics Global has a 52-week low of $3.09 and a 52-week high of $22.86.

Institutional Investors Weigh In On Prenetics Global

Several hedge funds have recently made changes to their positions in the stock. Stevens Capital Partners lifted its position in shares of Prenetics Global by 4.7% in the 4th quarter. Stevens Capital Partners now owns 18,207 shares of the company’s stock worth $287,000 after acquiring an additional 825 shares during the period. Wells Fargo & Company MN acquired a new position in shares of Prenetics Global in the fourth quarter valued at $47,000. JPMorgan Chase & Co. bought a new position in Prenetics Global in the third quarter worth $65,000. T3 Companies LLC acquired a new stake in Prenetics Global during the fourth quarter worth $170,000. Finally, Kingsview Wealth Management LLC bought a new stake in Prenetics Global in the 4th quarter valued at $172,000. Institutional investors own 25.01% of the company’s stock.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.